Published in final edited form as:

Chembiochem. 2016 January ; 17(2): 174–180. doi:10.1002/cbic.201500499.

Chemical Synthesis of GM2 Glycans, Bioconjugation with Bacteriophage Q β , and the Induction of Anticancer Antibodies

Dr. Zhaojun Yin^{[a],+}, Steven Dulaney^{[a],+}, Dr. Craig S. McKay^[b], Claire Baniel^[a], Dr. Katarzyna Kaczanowska^[b], Sherif Ramadan^{[a],[c]}, Prof. Dr. M. G. Finn^[b], and Prof. Dr. Xuefei Huang^[a]

Xuefei Huang: xuefei@chemistry.msu.edu

^[a]Department of Chemistry, Michigan State University 578 S. Shaw Lane, Room 426, East Lansing, MI 48824-1322 (USA)

^[b]School of Chemistry and Biochemistry, Georgia Institute of Technology 901 Atlantic Drive, Atlanta, GA 30332-0400 (USA)

Abstract

The development of carbohydrate-based antitumor vaccines is an attractive approach towards tumor prevention and treatment. Herein, we focused on the ganglioside GM2 tumor-associated carbohydrate antigen (TACA), which is overexpressed in a wide range of tumor cells. GM2 was synthesized chemically and conjugated with a virus-like particle derived from bacteriophage Q β . Although the copper-catalyzed azide–alkyne cyclo-addition reaction efficiently introduced 237 copies of GM2 per Q β , this construct failed to induce significant amounts of anti-GM2 antibodies compared to the Q β control. In contrast, GM2 immobilized on Q β through a thiourea linker elicited high titers of IgG antibodies that recognized GM2-positive tumor cells and effectively induced cell lysis through complement-mediated cytotoxicity. Thus, bacteriophage Q β is a suitable platform to boost antibody responses towards GM2, a representative member of an important class of TACA: the ganglioside.

Keywords

antibodies; carbohydrates; immunology; synthesis; vaccines

Introduction

Aberrant glycosylation is a hallmark of many human cancers.^[1–4] Tumor-associated carbohydrate antigens (TACAs) are attractive targets for antitumor vaccines, due to their high levels of expression in tumor cells.^[5–8] However, the development of an effective

Correspondence to: Xuefei Huang, xuefei@chemistry.msu.edu.

^[c]Current address: Chemistry Department, Faculty of Science, Benha University Benha, Qaliobiya (Egypt)

⁺These authors contributed equally to this work.

The authors declare no competing financial interests.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/cbic.201500499>; synthetic procedures and characterization data of GM2 and Q β –GM2 conjugates; NMR and MS spectra for key compounds.

carbohydrate-based antitumor vaccine is extremely challenging. In nature, TACAs are often expressed as a heterogeneous mixture. As a result, it is difficult to obtain sufficient quantities of TACAs in conjugatable forms through isolation. In addition, there are concerns of highly active trace contaminants present in isolated samples. Thus, synthesis becomes critical to produce these complex molecules.^[9–10]

In addition to the challenge of accessing TACAs, the immunological obstacle is that TACAs are T cell-independent B cell antigens.^[5–8] When administered alone, they generally produce low titers of low-affinity IgM antibodies, which do not persist for a long time. To induce high-affinity IgG antibodies, a typical approach is to conjugate TACAs with carriers containing helper T (Th) cell epitopes, which include immunogenic proteins,^[10–11] peptides,^[6,12–13] multiple antigenic glycopeptides,^[14–15] nanoparticles,^[16–18] polymers,^[18–20] and polysaccharides.^[21] Recently, we have demonstrated that self-assembled virus-like particles (VLPs) could be used to deliver a TACA, the Tn antigen, to the immune system and generate powerful antibody responses.^[22–25] The induced antibodies bound strongly with Tn-expressing tumor cells, resulting in tumor cell death and protection of immunized mice from tumor development.^[22]

Building on the success of the VLP–Tn studies, we became interested in testing whether the VLP platform could potentially induce antibody responses against another important family of TACAs, that is, the gangliosides,^[3] as represented by GM2. GM2 contains a sialic-acid-terminated branched tetrasaccharide linked to a ceramide chain. GM2 is expressed on the surfaces of a wide range of human cancers, which include cancer cells of neuroectodermal origin (melanoma, sarcoma, and neuroblastoma), as well as epithelial cancers, such as breast and prostate cancers.^[7,26,27] The wide expression of GM2 on multiple types of cancers renders it an intriguing target for developing a potentially universal anticancer vaccine. In addition, clinical studies have shown that elevated levels of anti-GM2 IgM antibodies are strongly associated with prolonged survival of melanoma patients.^[28–29] Both passive administration of anti-GM2 monoclonal antibodies^[30] and active immunity gained through vaccination^[28,31] could lead to favorable prognosis, such as tumor regression or longer disease-free intervals. These clinical outcomes have inspired the drive towards GM2-based anticancer vaccines.^[28,32–34]

The generation of antibodies is a highly complex process. Many structural features of the construct can significantly impact the results of antibody responses. Livingston and coworkers showed that anti-GM2 antibody titers were highly dependent upon the carrier moiety of the vaccine construct.^[35] The Lo-Man group demonstrated that GM2 coupled with a Th epitope through a copper-catalyzed azide–alkyne cycloaddition (CuAAC) reaction gave good titers of anti-GM2 antibodies.^[34] Yet, when the same Th cell peptide was

conjugated with two GM2 molecules, despite the higher valency, it failed to elicit detectable levels of IgM or IgG antibodies in mice, even after repeated immunizations. Thus, the structure of a vaccine construct needs to be carefully designed and evaluated. Herein, we report our results using synthetic GM2 antigens arrayed over the surface of the VLP bacteriophage Q β capsid for the induction of antitumor antibodies.

Results and Discussion

Prior anti-GM2 vaccine studies have primarily utilized GM2 glycan extracted from mammalian tissues^[28,32] or enzymatically synthesized.^[33–34,36] Chemical synthesis can bestow flexibility in functionalizing the antigen for immunological investigations. Although GM2 glycans have been chemically synthesized previously,^[37–39] with the need for stereoselective sialylation and formation of branched glycans, its preparation in a conjugatable form is not a trivial task. Our synthetic target was the GM2 tetrasaccharide **1**, bearing a reducing end free amine, which was prepared by regioselective sialylation of the lactosyl diol acceptor **2** by sialyl donor **3**, followed by glycosylation of the 4'-OH by galactosamine (GalN) donor **4** (Scheme 1).

Our synthesis commenced with lactoside **5**,^[40] which was derived from D-lactose and subsequently transformed to diol **2** through protecting group manipulations (Scheme 2 A). Sialylation of acceptor **2** was performed with thiosialoside donor **3**. Initial coupling of **2** and **3** was mediated by using *N*-iodosuccinimide (NIS) and triflic acid as the promoter, which gave desired α -sialoside **6** in 42 % yield, along with 8 % of the β -anomer. The stereochemistry of the newly formed glycosyl linkage of **6** was assigned based on the 3-bond coupling constant between C1 and H3_{ax} of sialic acid ($^3J_{C1,H3ax} = 8$ Hz), as well as that between H7 and H8 of sialic acid ($^3J_{H7,H8} = 7.9$ Hz).^[41–42] Regioselectivity was confirmed by the correlation between C2 of sialic acid with H3' of the lactose unit in the HMBC NMR spectrum. In order to improve the sialylation yield, various reaction conditions were examined. Whereas changing the solvent, reaction time, or temperature did not lead to significant enhancements, the combination of *p*-TolSCI/AgOTf^[43–44] as the promoter system improved the yield of **6** to 65%. Recently, modified sialyl donors with groups such as 4-*O*,5-*N*-oxazolidinone and 5-*N*-trifluoroacetyl have been shown to give high yields and stereoselectivities in sialylation reactions.^[45–49] Donor **3** has the advantage that no additional synthetic steps were needed to adjust the protecting groups on C5 of sialic acid, while achieving good yield and stereoselectivity. With trisaccharide **6** in hand, glycosylation by the GalN donor **4** was carried out by using the *p*-TolSCI/AgOTf promoter system, producing the protected GM2 **7** in 63 % yield, with the new glycosidic bond being exclusively β ($^1J_{H1,C1}$ of GalN = 161.4 Hz,^[50] $^3J_{H1,H2}$ of GalN = 8.8 Hz).

Compound **7** was deprotected in four steps, starting from the hydrolysis of *O*-acetyl groups concomitant with Troc removal (Scheme 2 B). The newly freed amino group on GalN was selectively acetylated with acetic anhydride in methanol. Finally, Staudinger reduction of the azido group and global debenzoylation with Pearlman's catalyst provided the fully deprotected GM2 tetrasaccharide **1** in 54 % yield over the four deprotection steps.

With the GM2 glycan in hand, we prepared a GM2 conjugate vaccine with the VLP bacteriophage Q β as the carrier, as we have previously shown that Q β is superior to several other VLP platforms in boosting anti-Tn immunity.^[23] Our initial approach for bioconjugation utilized the CuAAC reaction, due to its high reaction rate, mild reaction conditions, and bioorthogonal nature.^[51–52] GM2 **1** was treated with activated ester **8** to attach an azide moiety to the reducing end for bioconjugation (GM2 **9**, 77 % yield; Scheme 3 A). Subsequently, **9** was coupled with the alkyne-functionalized Q β **10** under CuAAC conditions, which introduced approximately 237 copies of GM2 antigen to each Q β capsid (Scheme 3B). The remaining free alkyne groups on Q β were capped with 3-azidopropan-1-ol **12** to afford Q β –GM2 **13**.

Next, the ability of Q β -GM2 **13** to generate anti-GM2 antibodies was evaluated. C57BL/6 mice were immunized subcutaneously with three biweekly injections of Q β -GM2 **13**, and sera from these mice were collected one week after the final boost injection. The control group of mice received the unconjugated Q β only. For enzyme-linked immunosorbent assay (ELISA) analysis of serum antibodies, a bovine serum albumin (BSA) conjugate of GM2 (BSA-GM2 **14**) was prepared through reductive amination with glutaraldehyde,^[53] with an average of 11 GM2 glycans coupled to BSA. ELISA analysis showed no significant binding to BSA-GM2 **14** by any post-immune sera, compared to the control sera from mice immunized with Q β only. To test serum binding with GM2 expressed in its native environment, that is, on the tumor cell surface, flow cytometry analysis of all sera were performed. None of the sera was able to bind with GM2-positive human lymphoma Jurkat cells, even at a relatively high concentration (1:10 dilution). These results demonstrated that Q β -GM2 **13** was unable to elicit high titers of anti-GM2 antibodies *in vivo*.

To better understand the Q β –GM2 **13** vaccine, the epitope profiles of antibodies generated were screened by ELISA. BSA conjugates to structural components of GM2—*N*-acetyl galactosamine (GalNAc),^[24] lactose, GM3, and BSA-triazole^[22]—were synthesized and immobilized on ELISA plates. Although there was some IgG binding to BSA–GalNAc, BSA–GM3, and BSA–GM2, the binding to BSA–triazole was significantly stronger (Figure 1). This suggests that the triazole linker is the dominant epitope among the components analyzed.

To avoid antibody responses to the triazole linker, alternative strategies were explored. Previously, we showed that reducing the number of triazoles on the Q β by removing the triazole used to cap the unreacted alkynes did not lead to enhanced anti-glycan responses.^[22] Therefore, we utilized another bioconjugation approach to ligate GM2 to Q β . Treatment of GM2 **1** with thiophosgene converted the amine group to isothiocyanate^[54] in 85 % yield (Scheme 3 C). The resulting GM2 **15** was incubated with wild-type Q β particle **16** at pH 8.5

to afford the Q β -GM2 conjugate **17**. This reaction proceeded smoothly, introducing an average of 220 copies of GM2 per Q β particle (Scheme 3 C).

With Q β -GM2 **17** in hand, mice were immunized. In contrast to Q β -GM2 **13**, ELISA analysis of post-immune sera showed good anti-GM2 IgG and IgM antibody responses, with IgG as the main antibody type (Figure 2A). The subclasses of IgG antibodies were also determined. The levels of IgG2 antibodies (IgG2b and IgG2) were much higher than those of IgG1 and IgG3, suggesting a more Th1-weighted immune response (Figure 2B).^[55–56] This is likely due to the ability of Q β to encapsulate single-stranded *Escherichia coli* RNA in the interior, which are potent agonists of Toll-like receptors **7** and **8** for immune potentiation favoring a Th1 response.^[57] The antibodies elicited by Q β -GM2 **17** were able to bind with multiple types of GM2-positive tumor cells, as determined by flow cytometry (Figure 2C and D), whereas sera from the control mice receiving Q β or the pre-immunized mice did not show any tumor cell recognition.

The epitope profiles of antibodies induced by Q β -GM2 **17** were analyzed by ELISA (Figure 1). The antibodies exhibited strongest binding to BSA-GM3, but the recognition of BSA-GalNAc and BSA-lactose was much weaker. This suggests that the sialic acid motif contains the major recognition sites of GM2. This observation is consistent with a literature report in which the removal of sialic acid from GM2 abrogated the binding by anti-GM2 polyclonal antibodies.^[34]

To assess the therapeutic potential of anti-GM2 antibodies, we evaluated the complement-dependent cytotoxicity against tumor cells. The classical pathway of complement activation is triggered by multivalent binding between the C1 complex and the Fc region of antibodies.^[58] Compared to other IgG subclasses, the IgG2 antibodies in mice have the strongest abilities to initiate the complement cascade.^[59] As shown in Figure 2E, the antibodies induced by Q β -GM2 **17** were able to efficiently kill GM2-positive Jurkat cells by the complement mechanism.

The CuAAC reaction and the triazole linker have been commonly used in carbohydrate-based vaccines.^[23–24,60–65] In our recent studies of Q β -Tn conjugates, we observed that the triazole-linked Q β -Tn failed to induce antibodies capable of recognizing Tn expressed on tumor cell TA3HA, which was attributed to the possible hindrance of Tn-specific B cell binding to the vaccine construct by anti-triazole antibodies.^[22] The inability of the triazole-containing Q β -GM2 **13** to generate anti-GM2 antibodies was consistent with the Q β -Tn results, suggesting that the detrimental effect of triazole on anti-TACA immunity was not restricted to a small antigen such as Tn, which contains only a monosaccharide *N*-acetyl

galactosamine linked with serine or threonine. Although the exact reasons for the suppressive effect of triazole on anti-GM2 antibody responses need further investigation, these results indicate that caution should be taken in applying CuAAC chemistry in future glycan-based vaccine design.

Compared to GM2 vaccine candidates reported to date,^[28,32–34] the Q β -GM2 **17** elicited similar total titers of anti-GM2 IgG antibodies and binding to GM2-positive tumor cells. Conjugates such as KLH-GM2 produced more IgG1 and IgG3 in human patients.^[35] Q β -GM2 **17** elicited higher titers of IgG2, which can be potentially advantageous for future clinical applications, as mouse IgG2s have been recognized as the most efficient IgG subclass to induce effector functions against tumor cells.^[66]

Conclusion

In conclusion, we have established an efficient chemical synthesis of GM2 glycans. The synthetic approach can bestow flexibilities to prepare GM2 derivatives such as GM2 lactones^[67–68] in the future to further enhance the immunogenicity of the antigen. In order to develop a GM2-based vaccine, our first-generation approach utilized the CuAAC reaction, linking 237 copies of GM2 onto a VLP carrier protein-bacteriophage Q β . However, no significant anti-GM2 antibodies were generated compared to the control. To overcome this obstacle, isothiocyanate chemistry was employed to introduce the GM2 glycan onto Q β . The resulting Q β -GM2 conjugate, **17**, was able to induce high titers of anti-GM2 antibodies, in particular IgG2 antibodies. The antibodies produced were capable of binding GM2-expressing tumor cells and exhibited complement-dependent cytotoxicity, lysing the tumor cells. Therefore, these results demonstrate that bacteriophage Q β can be an effective vaccine platform for a GM2-based vaccine. Studies are ongoing to optimize the GM2 antigen structure, as well as the vaccine construct, to further enhance vaccine efficacy.

Experimental Section

Immunization of mice

Pathogen-free C57BL/6 female mice age 6–10 weeks were obtained from Charles River and maintained in the University Laboratory Animal Resources facility of Michigan State University. All animal care procedures and experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Michigan State University. Groups of five C57BL/6 mice were injected subcutaneously under the scruff on day 0 with 0.1 mL of various Q β constructs as emulsions in complete Freund's adjuvant (Sigma-Aldrich, F5881), and boosters were given subcutaneously under the scruff on days 14 and 28 with various Q β constructs (0.1 mL) as emulsions in incomplete Freund's adjuvant (Sigma-Aldrich, F5506). All GM2 vaccine constructs administered had the same amounts of GM2 antigen (4 μ g). Serum samples were collected on days 0 (before immunization), 7, and 35. The final bleeding was done by cardiac bleed. Statistical analysis of immune responses of various groups were performed by Student's t-test.

Antibody detection by ELISA and flow cytometry

Sera were tested as described previously for anti-Tn and anti-triazole antibodies by ELISA. The titer was determined by regression analysis with the log10 dilution plotted against optical density.

Sera were tested by flow cytometry on GM2-bearing Jurkat (kindly provided by Profs. Barbara Kaplan and Norbert Kaminski, Michigan State University) and MCF-7 (kindly provided by Prof. Olivera J. Finn, University of Pittsburgh) tumor cell lines. Cells were incubated with 1:20 diluted mice sera on ice for 30 min and then labeled with goat anti-mouse IgG conjugated with FITC (BioLegend, 405305) for 30 min. Acquisition of cells was performed with LSR II (BD), and data were analyzed with FlowJo software (Tree Star, Inc.).

Complement-dependent cytotoxicity

Mice sera were diluted with DMEM medium (10 % FBS, without phenol red), mixed with 10^5 Jurkat cells and incubated on ice for 45 min. The 96-well plate was then centrifuged, and the supernatant was discarded. A final concentration of 10% baby rabbit complement (Cedarlane, CL3441-S) in DMEM medium was added and incubated at 37°C for 4 h. After centrifugation, 50 μ L of the supernatant was transferred to a new 96-well plate, mixed with 50 μ L of a lactose dehydrogenase substrate (CytoTox 96 nonradioactive cytotoxicity kit, G1780, Promega) and incubated at room temperature for 15 min, followed by addition of 50 μ L stopping buffer. The plate was then read at 490 nm. The percentage of specific cell lysis was calculated as follows: $[(A-C)/(B-C)] \times 100$, where *A* represents absorbance obtained from mouse sera, *B* represents maximal lysis obtained by treating Jurkat cells with lysis buffer from kit, and *C* represents spontaneous lysis by treating Jurkat cells with complement only.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to the National Cancer Institute (R01A149451-01A1) for financial support of our work.

References

1. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. Breast Cancer Res. 2010; 12:204. [PubMed: 20550729]
2. Hakomori S. Adv Exp Med Biol. 2001; 491:369–402. [PubMed: 14533809]
3. Hakomori S, Zhang Y. Chem Biol. 1997; 4:97–104. [PubMed: 9190292]
4. Vasconcelos-dos-Santos A, Oliveira IA, Lucena MC, Mantuano NR, Whelan SA, Dias WB, Todeschini AR. Front Oncol. 2015; 5:138. [PubMed: 26161361]
5. Guo Z, Wang Q. Curr Opin Chem Biol. 2009; 13:608–617. [PubMed: 19766052]
6. Buskas T, Thompson P, Boons G-J. Chem Commun. 2009:5335–5349.
7. Yin Z, Huang X. J Carbohydr Chem. 2012; 31:143–186. and references therein. [PubMed: 22468019]
8. Liu CC, Ye XS. Glycoconjugate J. 2012; 29:259–271.
9. Galonic DP, Gin DY. Nature. 2007; 446:1000–1007. [PubMed: 17460660]

10. Danishefsky SJ, Allen JR. *Angew Chem Int Ed.* 2000; 39:836–863. *Angew Chem.* 2000; 112:882–912.
11. Livingston PO, Ragupathi G. *Human Vaccines.* 2006; 2:137–143. and references therein. [PubMed: 17012906]
12. Wilkinson BL, Day S, Malins LR, Apostolopoulos V, Payne RJ. *Angew Chem Int Ed.* 2011; 50:1635–1639. *Angew Chem.* 2011; 123:1673–1677.
13. Gaidzik N, Westerlind U, Kunz H. *Chem Soc Rev.* 2013; 42:4421–4442. and references therein. [PubMed: 23440054]
14. Lo-Man R, Vichier-Guerre S, Bay S, Deriaud E, Cantacuzene D, Leclerc C. *J Immunol.* 2001; 166:2849–2854. [PubMed: 11160353]
15. Lo-Man R, Vichier-Guerre S, Perraut R, Deriaud E, Huteau V, BenMohamed L, Diop OM, Livingston PO, Bay S, Leclerc C. *Cancer Res.* 2004; 64:4987–4994. [PubMed: 15256473]
16. Brinãs RP, Sundgren A, Sahoo P, Morey S, Rittenhouse-Olson K, Wilding GE, Deng W, Barchi JJ. *Bioconjugate Chem.* 2012; 23:1513–1523.
17. Sungsuwan S, Yin Z, Huang X. *ACS Appl Mater Interfaces.* 2015; 7:17535–17544. [PubMed: 26200668]
18. Parry AL, Clemson NA, Ellis J, Bernhard SSR, Davis BG, Cameron NR. *J Am Chem Soc.* 2013; 135:9362–9365. [PubMed: 23763610]
19. Qin Q, Yin Z, Bentley P, Huang X. *Med Chem Comm.* 2014; 5:1126–1129.
20. Nuhn L, Hartmann S, Palitzsch B, Gerlitzki B, Schmitt E, Zentel R, Kunz H. *Angew Chem Int Ed.* 2013; 52:10652–10656. *Angew Chem.* 2013; 125:10846–10850.
21. De Silva RA, Wang Q, Chidley T, Appulage DK, Andreana PR. *J Am Chem Soc.* 2009; 131:9622–9623. [PubMed: 19552408]
22. Yin Z, Wright WS, McKay C, Baniel C, Kaczanowska K, Bentley P, Gildersleeve JC, Finn MG, BenMohamed L, Huang X. *ACS Chem Biol.* 2015; 10:2364–2372. [PubMed: 26262839]
23. Yin Z, Comellas-Aragones M, Chowdhury S, Bentley P, Kaczanowska K, BenMohamed L, Gildersleeve JC, Finn MG, Huang X. *ACS Chem Biol.* 2013; 8:1253–1262. [PubMed: 23505965]
24. Yin Z, Nguyen HG, Chowdhury S, Bentley P, Bruckman MA, Miermont A, Gildersleeve JC, Wang Q, Huang X. *Bioconjugate Chem.* 2012; 23:1694–1703.
25. Miermont A, Barnhill H, Strable E, Lu X, Wall KA, Wang Q, Finn MG, Huang X. *Chem Eur J.* 2008; 14:4939–4947. [PubMed: 18431733]
26. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO. *Int J Cancer.* 1997; 73:42–49. [PubMed: 9334808]
27. Ritter G, Livingston PO. *Semin Cancer Biol.* 1991; 2:401–409. [PubMed: 1810468]
28. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, Oettgen HF, Old LJ. *J Clin Oncol.* 1994; 12:1036–1044. [PubMed: 8164027]
29. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF. *J Natl Cancer Inst.* 1981; 66:249–254. [PubMed: 6935475]
30. Irie R, Matsuki T, Morton D. *Lancet.* 1989; 333:786–787. [PubMed: 2564593]
31. Livingston PO, Natoli EJJ, Calves MJ, Stockert E, Oettgen HFO, Old LJ. *Proc Natl Acad Sci USA.* 1987; 84:2911–2915. [PubMed: 3472242]
32. Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO. *Clin Cancer Res.* 2000; 6:874–879. [PubMed: 10741710]
33. Rich JR, Wakarchuk WW, Bundle DR. *Chem Eur J.* 2006; 12:845–858. [PubMed: 16196067]
34. Bay S, Fort S, Birikaki L, Ganneau C, Samain E, Coic YM, Bonhomme F, Deriaud E, Leclerc C, Lo-Man R. *Chem Med Chem.* 2009; 4:582–587. [PubMed: 19226501]
35. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO. *Cancer Res.* 1995; 55:2783–2788. [PubMed: 7796403]
36. Jacques S, Rich JR, Ling CC, Bundle DR. *Org Biomol Chem.* 2006; 4:142–154. [PubMed: 16358009]
37. Castro-Palomino JC, Ritter G, Fortunato SR, Reinhardt S, Old LJ, Schmidt RR. *Angew Chem Int Ed Engl.* 1997; 36:1998–2001. *Angew Chem.* 1997; 109:2081–2085.

38. Cho YS, Wan Q, Danishefsky SJ. *Bioorg Med Chem*. 2005; 13:5259–5266. [PubMed: 16006132]
39. Sugimoto M, Numata M, Koike K, Nakahara Y, Ogawa T. *Carbohydr Res*. 1986; 156:C1–5. [PubMed: 3815403]
40. Sun B, Yang B, Huang X. *Sci China Chem*. 2012; 55:31–35. [PubMed: 22389646]
41. Paulsen H, Tietz H. *Angew Chem Int Ed Engl*. 1982; 21:927–928. *Angew Chem*. 1982; 94:934–935.
42. Boons GJ, Demchenko AV. *Chem Rev*. 2000; 100:4539–4566. [PubMed: 11749357]
43. Huang X, Huang L, Wang H, Ye XS. *Angew Chem Int Ed*. 2004; 43:5221–5224. *Angew Chem*. 2004; 116:5333–5336.
44. Sun B, Srinivasan B, Huang X. *Chem Eur J*. 2008; 14:7072–7081. [PubMed: 18601234]
45. Kancharla PK, Navuluri C, Crich D. *Angew Chem Int Ed*. 2012; 51:11105–11109. *Angew Chem*. 2012; 124:11267–11271.
46. Zhang XT, Gu ZY, Xing GW. *Carbohydr Res*. 2014; 388:1–7. and references therein. [PubMed: 24594527]
47. Tanaka H, Nishiura Y, Takahashi T. *J Am Chem Soc*. 2006; 128:7124–7125. [PubMed: 16734441]
48. De Meo C, Farris M, Ginder N, Gulley B, Priyadarshani U, Woods M. *Eur J Org Chem*. 2008:3673–3677.
49. Lin CC, Huang KT, Lin CC. *Org Lett*. 2005; 7:4169–4172. [PubMed: 16146379]
50. Bock K, Pedersen C. *J Chem Soc Perkin Trans 2*. 1974:293–297.
51. Finn MG, Fokin VV. *Chem Soc Rev*. 2010; 39:1231–1232. and references therein. [PubMed: 20309482]
52. Hong V, Presolski SI, Ma C, Finn MG. *Angew Chem Int Ed*. 2009; 48:9879–9883. *Angew Chem*. 2009; 121:10063–10067.
53. Migneault I, Dartiguenave C, Bertrand MJ, Waldron KC. *Biotechniques*. 2004; 37:790–802. [PubMed: 15560135]
54. Smith DF, Zopf DA, Ginsburg V. *Methods Enzymol*. 1978; 50:169–171. [PubMed: 661573]
55. Lefeber DJ, Benaissa-Trouw B, Vliegthart JFG, Kamerling JP, Jansen WTM, Kraaijeveld K, Snippe H. *Infect Immun*. 2003; 71:6915–6920. [PubMed: 14638780]
56. Germann T, Bongartz M, Dlugonska H, Hess H, Schmitt E, Kolbe L, Kölsch E, Podlaski FJ, Gately MK, Rüde E. *Eur J Immunol*. 1995; 25:823–829. [PubMed: 7705414]
57. Schön MP, Schön M. *Oncogene*. 2008; 27:190–199. [PubMed: 18176600]
58. Schumaker VN, Zavodszky P, Poon PH. *Annu Rev Immunol*. 1987; 5:21–42. [PubMed: 3036181]
59. Jansen JL, Gerard AP, Kamp J, Tamboer WP, Wijdeveld PG. *J Immunol*. 1975; 115:387–391. [PubMed: 807636]
60. Kaltgrad E, Sen Gupta S, Punna S, Huang CY, Chang A, Wong CH, Finn MG, Blixt O. *Chem Bio Chem*. 2007; 8:1455–1462.
61. Astronomo RD, Kaltgrad E, Udit A, Wang SK, Doores KJ, Huang CY, Pantophlet R, Paulson JC, Wong CH, Finn MG, Burton DR. *Chem Biol*. 2010; 17:357–370. [PubMed: 20416507]
62. Lipinski T, Luu T, Kitov PI, Szpacenko A, Bundle DR. *Glycoconjugate J*. 2011; 28:149–164.
63. Wang Q, Zhou Z, Tang S, Guo Z. *ACS Chem Biol*. 2012; 7:235–240. [PubMed: 22013921]
64. Hu QY, Allan M, Adamo R, Quinn D, Zhai HL, Wu GX, Clark K, Zhou J, Ortiz S, Wang B, Danieli E, Crotti S, Tontini M, Brogioni G, Berti F. *Chem Sci*. 2013; 4:3827–3832.
65. Cai H, Sun ZY, Chen MS, Zhao YF, Kunz H, Li YM. *Angew Chem Int Ed*. 2014; 53:1699–1703. *Angew Chem*. 2014; 126:1725–1729.
66. Nimmerjahn F, Ravetch JV. *Science*. 2005; 310:1510–1512. [PubMed: 16322460]
67. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. *Int J Cancer*. 2000; 85:659–666. [PubMed: 10699946]
68. Ritter G, Boosfeld E, Adluri R, Calves M, Oettgen HF, Old LJ, Livingston P. *Int J Cancer*. 1991; 48:379–385. [PubMed: 2040532]

Figure 1.

ELISA analysis of the epitope profiles of post-immune sera from mice immunized with triazole linked Qβ-GM2 conjugate **13** and thiourea-linked Qβ-GM2 **17**, respectively. For **13**, the anti-triazole antibody level was significantly higher for than other types of antibodies, such as anti-GM2 or anti-GM3 antibodies ($p < 0.0001$). Qβ-GM2 **17** induced significantly higher anti-GM2 antibodies ($p = 0.002$) but much lower levels of anti-triazole antibodies ($p < 0.0001$) than did **13**. Sera from each group were analyzed at 1600-fold dilution. The average of optical density value and SEM were shown. Statistics were performed by Student's t-test.

Figure 2.

Immunological evaluation of Q β -GM2 conjugate vaccine **17**. A) IgM and IgG titers of anti-GM2 antibodies tested by ELISA. Sera from mice immunized with wild-type Q β particle were tested as a control. B) The levels of anti-GM2 IgG subclasses as determined by ELISA. Sera were tested at 1:1000 dilution. C) Binding of GM2-expressing Jurkat cells and D) MCF-7 cells with representative mouse sera diluted at 1:20. Gray filled: pre-immune sera and sera from mice immunized with Q β only; solid line: day 35 sera from a mouse immunized with Q β -GM2 **17**. E) Complement-dependent toxicity against Jurkat cells as measured by LDH assay. Sera from two mice immunized with Q β -GM2 **17** are shown (mouse 1: ■, mouse 2: ▲). Pre-immune serum was utilized as a control (●). Sera from mice immunized with Q β gave similar results as the pre-immune sera.

Scheme 1.
Retrosynthetic analysis of GM2 tetrasaccharide **1**.

Scheme 2.

Synthesis of GM2 tetrasaccharide **1**. a) NaN_3 , DMF; b) NaOMe, MeOH; c) acetone, *p*-TsOH, 2,2-dimethoxypropane; d) NaH, BnBr, DMF; e) TFA, CH_2Cl_2 , (44 % for five steps); f) sialyl donor **3**, *p*-TolSCl, AgOTf, -40°C , MeCN (65 %); g) GalN donor **4**, *p*-TolSCl, AgOTf, -78°C , CH_2Cl_2 , Et_2O (63 %); h) NaOH, THF; i) Ac_2O , TEA, MeOH; j) PMe_3 , NaOH; k) $\text{Pd}(\text{OH})_2$, H_2 (54 % for four steps).

Scheme 3.

Synthesis of GM2–Q β conjugates. a) NaHCO₃, H₂O; b) CuSO₄, sodium ascorbate, THPTA, PBS buffer (CuAAC conditions); c) thiophosgene, NaHCO₃, CHCl₃/H₂O; d) Na₂B₄O₇ buffer (pH 8.5).